79 research outputs found

    High School Choice in New York City: A Report on the School Choices and Placements of Low-Achieving Students

    Get PDF
    School choice policies, a fixture of efforts to improve public education in many cities. aim to enable families to choose a school that they believe will best meet their child's needs. In New York City, choice and the development of a diverse portfolio of options have played central roles in the Department of Education's high school reform efforts. This report examines the choices and placements of New York City's lowest-achieving students: those scoring among the bottom 20 percent on standardized state tests in middle school. Focusing on data from 2007 to 2011, the report looks at who these low-achieving students are, including how their demographics compare to other students in NYC, the educational challenges they face, and where they live. The bulk of the report reviews low-achieving students' most preferred schools and the ones to which they were ultimately assigned, assessing how these schools compare to those of their higher-achieving peers. The findings show that low-achieving students attended schools that were lower performing, on average, than those of all other students. This was driven by differences in students' initial choices: low-achieving students' first-choice schools were less selective, lower-performing, and more disadvantaged. Overall, lower-achievingand higher-achieving students were matched to their top choices at the same rate. Importantly, both low- and higher-achieving students appear to prefer schools that are close to home, suggesting that differences in students' choices likely reflect, at least in part, the fact that lower-achieving students are highly concentrated in poor neighborhoods, where options may be more limited

    Changing Labor Market Opportunities for Women and the Quality of Teachers 1957-1992

    Get PDF
    School officials and policy makers have grown increasingly concerned about their ability to attract and retain talented teachers. A number of authors have shown that in recent years the brightest students at least those with the highest verbal and math scores on standardized tests are less likely to enter teaching. In addition, it is frequently claimed that the ability of schools to attract these top students has been steadily declining for years. There is, however, surprisingly little evidence measuring the extent to which this popular proposition is true. We have good reason to suspect that the quality of those entering teaching has fallen over time. Teaching has remained a predominately female profession for years; at the same time, the employment opportunities for talented women outside of teaching have soared. In this paper, we combine data from four longitudinal surveys of high school graduates spanning the years 1957-1992 to examine how the propensity for talented women to enter teaching has changed over time. We find that while the quality of the average new female teacher has fallen only slightly over this period, the likelihood that a female from the top of her high school class will eventually enter teaching has fallen dramatically from 1964 to 1992 by our estimation, from almost 20% to under 4%.

    Pathways to an Elite Education: Exploring Strategies to Diversify NYC's Specialized High Schools

    Get PDF
    NYC's specialized high schools are well known for their elite academics, but also heavily criticized for their lack of diversity. Indeed, girls and, most starkly, Black and Latino students are under-represented at the schools. A central question has been the extent to which the schools' admissions policy -- which admits students solely based on their performance on the Specialized High School Admissions Test (SHSAT) -- is to blame.This brief examines students' pathways from middle school to matriculation at a specialized high school, and simulates the effects of various admissions criteria that have been proposed as alternatives to the current policy. Analyzing data from 2005 to 2013, we found that while the SHSAT is (by design) the most important factor determining who attends the specialized high schools, it is not the only factor. Many students -- including many high-achieving students -- do not take the SHSAT at all, and some of those offered admission decide to go to high school elsewhere.Overall, our findings show that the disparities in the specialized high schools largely reflect system-wide inequalities. By any standardized measure, Black, Latino and low-income students are under-represented among the City's "highest achievers." Future Research Alliance work will dig into these systemic inequalities, aiming to identify strategies to expand access for traditionally disadvantaged students

    Pathways to an Elite Education: Application, Admission, and Matriculation to New York City's Specialized High Schools (Working Paper)

    Get PDF
    New York City's elite public specialized high schools have a long history of offering a rigorous college preparatory education to the City's most academically talented students. Though immensely popular and highly selective, their policy of admitting students on the basis of a single entrance exam has been heavily criticized. Many argue, for example, that the policy inhibits diversity at the schools, which are predominately Asian, White, and male. In this paper, we provide a descriptive analysis of the "pipeline" from middle school to matriculation at a specialized high school, identifying group-level differences in rates of application, admission, and enrollment unexplained by measures of prior achievement. These differences serve to highlight points of intervention to improve access for under-represented groups. We also look at the role of middle schools in the pipeline, examining the distribution of offers across middle schools and testing for middle school effects on application and admission. Finally, we simulate the effects of alternative admissions rules on the composition of students at the specialized high schools

    Practical guidelines for rigor and reproducibility in preclinical and clinical studies on cardioprotection

    Get PDF
    The potential for ischemic preconditioning to reduce infarct size was first recognized more than 30 years ago. Despite extension of the concept to ischemic postconditioning and remote ischemic conditioning and literally thousands of experimental studies in various species and models which identified a multitude of signaling steps, so far there is only a single and very recent study, which has unequivocally translated cardioprotection to improved clinical outcome as the primary endpoint in patients. Many potential reasons for this disappointing lack of clinical translation of cardioprotection have been proposed, including lack of rigor and reproducibility in preclinical studies, and poor design and conduct of clinical trials. There is, however, universal agreement that robust preclinical data are a mandatory prerequisite to initiate a meaningful clinical trial. In this context, it is disconcerting that the CAESAR consortium (Consortium for preclinicAl assESsment of cARdioprotective therapies) in a highly standardized multi-center approach of preclinical studies identified only ischemic preconditioning, but not nitrite or sildenafil, when given as adjunct to reperfusion, to reduce infarct size. However, ischemic preconditioning—due to its very nature—can only be used in elective interventions, and not in acute myocardial infarction. Therefore, better strategies to identify robust and reproducible strategies of cardioprotection, which can subsequently be tested in clinical trials must be developed. We refer to the recent guidelines for experimental models of myocardial ischemia and infarction, and aim to provide now practical guidelines to ensure rigor and reproducibility in preclinical and clinical studies on cardioprotection. In line with the above guideline, we define rigor as standardized state-of-the-art design, conduct and reporting of a study, which is then a prerequisite for reproducibility, i.e. replication of results by another laboratory when performing exactly the same experiment

    Prevalence, associated factors and outcomes of pressure injuries in adult intensive care unit patients: the DecubICUs study

    Get PDF
    Funder: European Society of Intensive Care Medicine; doi: http://dx.doi.org/10.13039/501100013347Funder: Flemish Society for Critical Care NursesAbstract: Purpose: Intensive care unit (ICU) patients are particularly susceptible to developing pressure injuries. Epidemiologic data is however unavailable. We aimed to provide an international picture of the extent of pressure injuries and factors associated with ICU-acquired pressure injuries in adult ICU patients. Methods: International 1-day point-prevalence study; follow-up for outcome assessment until hospital discharge (maximum 12 weeks). Factors associated with ICU-acquired pressure injury and hospital mortality were assessed by generalised linear mixed-effects regression analysis. Results: Data from 13,254 patients in 1117 ICUs (90 countries) revealed 6747 pressure injuries; 3997 (59.2%) were ICU-acquired. Overall prevalence was 26.6% (95% confidence interval [CI] 25.9–27.3). ICU-acquired prevalence was 16.2% (95% CI 15.6–16.8). Sacrum (37%) and heels (19.5%) were most affected. Factors independently associated with ICU-acquired pressure injuries were older age, male sex, being underweight, emergency surgery, higher Simplified Acute Physiology Score II, Braden score 3 days, comorbidities (chronic obstructive pulmonary disease, immunodeficiency), organ support (renal replacement, mechanical ventilation on ICU admission), and being in a low or lower-middle income-economy. Gradually increasing associations with mortality were identified for increasing severity of pressure injury: stage I (odds ratio [OR] 1.5; 95% CI 1.2–1.8), stage II (OR 1.6; 95% CI 1.4–1.9), and stage III or worse (OR 2.8; 95% CI 2.3–3.3). Conclusion: Pressure injuries are common in adult ICU patients. ICU-acquired pressure injuries are associated with mainly intrinsic factors and mortality. Optimal care standards, increased awareness, appropriate resource allocation, and further research into optimal prevention are pivotal to tackle this important patient safety threat

    Effect of angiotensin-converting enzyme inhibitor and angiotensin receptor blocker initiation on organ support-free days in patients hospitalized with COVID-19

    Get PDF
    IMPORTANCE Overactivation of the renin-angiotensin system (RAS) may contribute to poor clinical outcomes in patients with COVID-19. Objective To determine whether angiotensin-converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) initiation improves outcomes in patients hospitalized for COVID-19. DESIGN, SETTING, AND PARTICIPANTS In an ongoing, adaptive platform randomized clinical trial, 721 critically ill and 58 non–critically ill hospitalized adults were randomized to receive an RAS inhibitor or control between March 16, 2021, and February 25, 2022, at 69 sites in 7 countries (final follow-up on June 1, 2022). INTERVENTIONS Patients were randomized to receive open-label initiation of an ACE inhibitor (n = 257), ARB (n = 248), ARB in combination with DMX-200 (a chemokine receptor-2 inhibitor; n = 10), or no RAS inhibitor (control; n = 264) for up to 10 days. MAIN OUTCOMES AND MEASURES The primary outcome was organ support–free days, a composite of hospital survival and days alive without cardiovascular or respiratory organ support through 21 days. The primary analysis was a bayesian cumulative logistic model. Odds ratios (ORs) greater than 1 represent improved outcomes. RESULTS On February 25, 2022, enrollment was discontinued due to safety concerns. Among 679 critically ill patients with available primary outcome data, the median age was 56 years and 239 participants (35.2%) were women. Median (IQR) organ support–free days among critically ill patients was 10 (–1 to 16) in the ACE inhibitor group (n = 231), 8 (–1 to 17) in the ARB group (n = 217), and 12 (0 to 17) in the control group (n = 231) (median adjusted odds ratios of 0.77 [95% bayesian credible interval, 0.58-1.06] for improvement for ACE inhibitor and 0.76 [95% credible interval, 0.56-1.05] for ARB compared with control). The posterior probabilities that ACE inhibitors and ARBs worsened organ support–free days compared with control were 94.9% and 95.4%, respectively. Hospital survival occurred in 166 of 231 critically ill participants (71.9%) in the ACE inhibitor group, 152 of 217 (70.0%) in the ARB group, and 182 of 231 (78.8%) in the control group (posterior probabilities that ACE inhibitor and ARB worsened hospital survival compared with control were 95.3% and 98.1%, respectively). CONCLUSIONS AND RELEVANCE In this trial, among critically ill adults with COVID-19, initiation of an ACE inhibitor or ARB did not improve, and likely worsened, clinical outcomes. TRIAL REGISTRATION ClinicalTrials.gov Identifier: NCT0273570
    • 

    corecore